Accolade Statistics
Total Valuation
RxSight has a market cap or net worth of $316.56 million. The enterprise value is $100.79 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 40.64 million shares outstanding. The number of shares has increased by 11.26% in one year.
| Current Share Class | 40.64M |
| Shares Outstanding | 40.64M |
| Shares Change (YoY) | +11.26% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 5.31% |
| Owned by Institutions (%) | 76.75% |
| Float | 29.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.14 |
| Forward PS | 2.05 |
| PB Ratio | 1.15 |
| P/TBV Ratio | 1.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.93, with a Debt / Equity ratio of 0.04.
| Current Ratio | 13.93 |
| Quick Ratio | 12.54 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,025.33 |
Financial Efficiency
Return on equity (ROE) is -11.66% and return on invested capital (ROIC) is -9.22%.
| Return on Equity (ROE) | -11.66% |
| Return on Assets (ROA) | -8.65% |
| Return on Invested Capital (ROIC) | -9.22% |
| Return on Capital Employed (ROCE) | -14.74% |
| Revenue Per Employee | $295,299 |
| Profits Per Employee | -$64,763 |
| Employee Count | 498 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.78 |
Taxes
In the past 12 months, RxSight has paid $75,000 in taxes.
| Income Tax | 75,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.72% in the last 52 weeks. The beta is 1.15, so RxSight's price volatility has been higher than the market average.
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -83.72% |
| 50-Day Moving Average | 11.35 |
| 200-Day Moving Average | 25.99 |
| Relative Strength Index (RSI) | 33.61 |
| Average Volume (20 Days) | 1,189,693 |
Short Selling Information
The latest short interest is 4.96 million, so 12.20% of the outstanding shares have been sold short.
| Short Interest | 4.96M |
| Short Previous Month | 5.79M |
| Short % of Shares Out | 12.20% |
| Short % of Float | 16.75% |
| Short Ratio (days to cover) | 2.56 |
Income Statement
In the last 12 months, RxSight had revenue of $147.06 million and -$32.25 million in losses. Loss per share was -$0.80.
| Revenue | 147.06M |
| Gross Profit | 107.53M |
| Operating Income | -42.53M |
| Pretax Income | -36.75M |
| Net Income | -32.25M |
| EBITDA | -39.32M |
| EBIT | -42.53M |
| Loss Per Share | -$0.80 |
Full Income StatementBalance Sheet
The company has $227.49 million in cash and $11.72 million in debt, giving a net cash position of $215.78 million or $5.31 per share.
| Cash & Cash Equivalents | 227.49M |
| Total Debt | 11.72M |
| Net Cash | 215.78M |
| Net Cash Per Share | $5.31 |
| Equity (Book Value) | 278.01M |
| Book Value Per Share | 6.80 |
| Working Capital | 263.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.82 million and capital expenditures -$4.06 million, giving a free cash flow of -$20.52 million.
| Operating Cash Flow | -16.82M |
| Capital Expenditures | -4.06M |
| Free Cash Flow | -20.52M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
Gross margin is 73.12%, with operating and profit margins of -28.92% and -21.93%.
| Gross Margin | 73.12% |
| Operating Margin | -28.92% |
| Pretax Margin | -21.88% |
| Profit Margin | -21.93% |
| EBITDA Margin | -26.74% |
| EBIT Margin | -28.92% |
| FCF Margin | n/a |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.26% |
| Shareholder Yield | -11.26% |
| Earnings Yield | -10.19% |
| FCF Yield | -6.48% |
Dividend DetailsAnalyst Forecast
The average price target for RxSight is $13.80, which is 77.15% higher than the current price. The consensus rating is "Hold".
| Price Target | $13.80 |
| Price Target Difference | 77.15% |
| Analyst Consensus | Hold |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 14.66% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
